Cargando…

Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda

Most studies evaluating BMD in human immunodeficiency virus (HIV)‐infected populations have focused on antiretroviral therapy (ART)‐experienced patients. In this study, the association between HIV‐1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV‐1–infected women in a res...

Descripción completa

Detalles Bibliográficos
Autores principales: Matovu, Flavia Kiweewa, Nabwana, Martin, Kiwanuka, Noah, Scholes, Delia, Isingel, Esther, Nolan, Monica L, Fowler, Mary G, Musoke, Philippa, Pettifor, John M, Brown, Todd T, Beksinska, Mags E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872338/
https://www.ncbi.nlm.nih.gov/pubmed/33615111
http://dx.doi.org/10.1002/jbm4.10446
_version_ 1783649169825595392
author Matovu, Flavia Kiweewa
Nabwana, Martin
Kiwanuka, Noah
Scholes, Delia
Isingel, Esther
Nolan, Monica L
Fowler, Mary G
Musoke, Philippa
Pettifor, John M
Brown, Todd T
Beksinska, Mags E
author_facet Matovu, Flavia Kiweewa
Nabwana, Martin
Kiwanuka, Noah
Scholes, Delia
Isingel, Esther
Nolan, Monica L
Fowler, Mary G
Musoke, Philippa
Pettifor, John M
Brown, Todd T
Beksinska, Mags E
author_sort Matovu, Flavia Kiweewa
collection PubMed
description Most studies evaluating BMD in human immunodeficiency virus (HIV)‐infected populations have focused on antiretroviral therapy (ART)‐experienced patients. In this study, the association between HIV‐1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV‐1–infected women in a resource‐limited setting was assessed before long‐term exposure to ART. The data were then compared with that of the 2005–2008 United States National Health and Nutrition Examination Survey data for non‐Hispanic White and Black women. Women aged 18–35 years, recruited from health facilities in Kampala, Uganda, were classified based on their combination of HIV‐1 status and DMPA use: (i) HIV‐1–infected current DMPA users, (ii) HIV‐1–infected previous DMPA users, (iii) HIV‐1–infected nonhormonal‐contraceptive users, and (iv) HIV‐uninfected nonhormonal‐contraceptive users. All HIV‐1–infected women reported being ART‐naïve at baseline. BMD was measured at the lumbar spine, total hip, and femoral neck using DXA. Multivariate linear regression was used to assess the association between HIV‐1 and/or DMPA and BMD Z‐scores. Baseline data were analyzed for 452 HIV‐1–infected (220 nonhormonal users, and 177 current and 55 previous DMPA users) and 69 HIV‐1–uninfected nonhormonal‐contraceptive users. The mean age was 26.1 years (SD, 4.2) with a median duration of DMPA use among current users of 24.0 months [medians (interquartile range), 12‐48]. A higher proportion of HIV‐1–infected previous (12.7%) or current DMPA users (20.3%) and nonhormonal users (15.0%) had low BMD (Z‐score ≤−2 at any of the three sites) compared with age‐matched HIV‐1–uninfected women (2.9%). HIV‐1 infection and DMPA use were independently associated with significantly lower mean BMD Z‐scores at all sites, with the greatest difference being among HIV‐1–infected current DMPA users (5.6%–8.0%) versus uninfected nonhormonal users. Compared with non‐Hispanic White and Black women, the Ugandan local reference population had generally lower mean BMD at all sites. Newer treatment interventions are needed to mitigate BMD loss in HIV‐1–infected women in resource‐limited settings. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7872338
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78723382021-02-19 Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda Matovu, Flavia Kiweewa Nabwana, Martin Kiwanuka, Noah Scholes, Delia Isingel, Esther Nolan, Monica L Fowler, Mary G Musoke, Philippa Pettifor, John M Brown, Todd T Beksinska, Mags E JBMR Plus Original Articles Most studies evaluating BMD in human immunodeficiency virus (HIV)‐infected populations have focused on antiretroviral therapy (ART)‐experienced patients. In this study, the association between HIV‐1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV‐1–infected women in a resource‐limited setting was assessed before long‐term exposure to ART. The data were then compared with that of the 2005–2008 United States National Health and Nutrition Examination Survey data for non‐Hispanic White and Black women. Women aged 18–35 years, recruited from health facilities in Kampala, Uganda, were classified based on their combination of HIV‐1 status and DMPA use: (i) HIV‐1–infected current DMPA users, (ii) HIV‐1–infected previous DMPA users, (iii) HIV‐1–infected nonhormonal‐contraceptive users, and (iv) HIV‐uninfected nonhormonal‐contraceptive users. All HIV‐1–infected women reported being ART‐naïve at baseline. BMD was measured at the lumbar spine, total hip, and femoral neck using DXA. Multivariate linear regression was used to assess the association between HIV‐1 and/or DMPA and BMD Z‐scores. Baseline data were analyzed for 452 HIV‐1–infected (220 nonhormonal users, and 177 current and 55 previous DMPA users) and 69 HIV‐1–uninfected nonhormonal‐contraceptive users. The mean age was 26.1 years (SD, 4.2) with a median duration of DMPA use among current users of 24.0 months [medians (interquartile range), 12‐48]. A higher proportion of HIV‐1–infected previous (12.7%) or current DMPA users (20.3%) and nonhormonal users (15.0%) had low BMD (Z‐score ≤−2 at any of the three sites) compared with age‐matched HIV‐1–uninfected women (2.9%). HIV‐1 infection and DMPA use were independently associated with significantly lower mean BMD Z‐scores at all sites, with the greatest difference being among HIV‐1–infected current DMPA users (5.6%–8.0%) versus uninfected nonhormonal users. Compared with non‐Hispanic White and Black women, the Ugandan local reference population had generally lower mean BMD at all sites. Newer treatment interventions are needed to mitigate BMD loss in HIV‐1–infected women in resource‐limited settings. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-12-21 /pmc/articles/PMC7872338/ /pubmed/33615111 http://dx.doi.org/10.1002/jbm4.10446 Text en © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Matovu, Flavia Kiweewa
Nabwana, Martin
Kiwanuka, Noah
Scholes, Delia
Isingel, Esther
Nolan, Monica L
Fowler, Mary G
Musoke, Philippa
Pettifor, John M
Brown, Todd T
Beksinska, Mags E
Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title_full Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title_fullStr Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title_full_unstemmed Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title_short Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
title_sort bone mineral density in antiretroviral therapy‐naïve hiv‐1–infected young adult ‐women using depot medroxyprogesterone acetate or nonhormonal contraceptives in uganda
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872338/
https://www.ncbi.nlm.nih.gov/pubmed/33615111
http://dx.doi.org/10.1002/jbm4.10446
work_keys_str_mv AT matovuflaviakiweewa bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT nabwanamartin bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT kiwanukanoah bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT scholesdelia bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT isingelesther bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT nolanmonical bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT fowlermaryg bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT musokephilippa bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT pettiforjohnm bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT browntoddt bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT beksinskamagse bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda
AT bonemineraldensityinantiretroviraltherapynaivehiv1infectedyoungadultwomenusingdepotmedroxyprogesteroneacetateornonhormonalcontraceptivesinuganda